CSF2 and temporal arteritis: This study demonstrates expression of GM-CSFRα, the target of mavrilimumab, within the lesions of GCA-affected arteries and confirms the increased production of GM-CSF previously reported.24 40 41 Macrophages were the main cell type immunostained for GM-CSF and GM-CSFRα in inflamed arteries.